Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,852 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bladder Clear all
Completed No phase listed Observational

Mass Spectrometry in Single Bladder Cancer Cells

NCT03639090
View directory record Official record
Conditions
Bladder Cancer
Interventions
mass spectrometry
Diagnostic Test
Lead sponsor
University of Oklahoma
Other
Eligibility
30 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 24, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children

NCT02204917
View directory record Official record
Conditions
Vesico-Ureteral Reflux
Interventions
OPTISON
Drug
Lead sponsor
Kassa Darge
Other
Eligibility
Up to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 24, 2026, 9:15 AM EDT
Completed Phase 2 Interventional

Study of Biomarkers and the Relaxation Response Using Guided Imagery in Women With IC

NCT00420550
View directory record Official record
Conditions
Interstitial Cystitis, Pelvic Pain
Interventions
Relaxation Response using Guided Imagery
Behavioral
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Oct 24, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking

NCT00365508
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
nicotine lozenge, nicotine patch
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Miami Beach, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 24, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead

NCT05799313
View directory record Official record
Conditions
Overactive Bladder
Interventions
At home removal, In office removal
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 24, 2026, 9:15 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

NCT04452591
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
45
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 24, 2026, 9:15 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder

NCT04020510
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 24, 2026, 9:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Sacituzumab Govitecan Plus EV in Metastatic UC

NCT04724018
View directory record Official record
Conditions
Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
Interventions
Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 24, 2026, 9:15 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Stress and Anxiety Effects on Overactive Bladder

NCT05087810
View directory record Official record
Conditions
Overactive Bladder, Stress, Psychological, Anxiety
Interventions
Psychological stress induction, Accelerated oral hydration
Behavioral · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 24, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

NCT06417190
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Tumor
Interventions
Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
Drug
Lead sponsor
Leslie Ballas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 24, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT05136898
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Homewood, Alabama • Indianapolis, Indiana • Greensboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 9:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms

NCT05162833
View directory record Official record
Conditions
Overactive Bladder
Interventions
TheraNova Neuromodulation Device
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Sacramento, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 24, 2026, 9:15 AM EDT
Not listed Phase 3 Interventional

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

NCT01050114
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 24, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Recovery of Bladder and Sexual Function After Human Spinal Cord Injury

NCT04193709
View directory record Official record
Conditions
Urinary Bladder, Neurogenic, Blood Pressure, Autonomic Dysreflexia, Bowel Incontinence
Interventions
Spinal Cord Epidural Stimulation
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 24, 2026, 9:15 AM EDT
Not listed Not applicable Interventional

Use of Pedometer Following Radical Cystectomy

NCT04305730
View directory record Official record
Conditions
Bladder Cancer, Ileus, Narcotic Use
Interventions
Use of a pedometer following surgery, Standard of care
Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 24, 2026, 9:15 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

NCT01200992
View directory record Official record
Conditions
Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
Interventions
EN3348, Mitomycin C
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 24, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

The Bladder Instillation Comparison Study

NCT02695771
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Mitomycin C, Gemcitabine
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 24, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Study of Tremelimumab in Patients With Advanced Solid Tumors

NCT02527434
View directory record Official record
Conditions
Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
San Francisco, California • Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 24, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

NCT02567409
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 24, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

NCT06331299
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-103
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Loma Linda, California • San Diego, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 9:15 AM EDT
Not listed No phase listed Observational

Treatment of Overactive Bladder With a Digital Conversational Agent: the MOTIVATION Study

NCT04853849
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Pelvic Floor Disorders
Interventions
Not listed
Lead sponsor
Renalis
Industry
Eligibility
40 Years and older · Female only
Enrollment
50 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 24, 2026, 9:15 AM EDT
Completed No phase listed Observational Results available

Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710

NCT02756637
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 24, 2026, 9:15 AM EDT
Completed Phase 2Phase 3 Interventional

Celecoxib in Treating Patients With Bladder Cancer

NCT00006124
View directory record Official record
Conditions
Recurrent Bladder Cancer
Interventions
celecoxib, placebo
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 24, 2026, 9:15 AM EDT
Terminated No phase listed Observational

Urodynamic Evaluation in Post-radiation Salvage Prostatectomy Patients

NCT00901420
View directory record Official record
Conditions
Prostate Cancer
Interventions
Urodynamics Test, Questionnaire
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 24, 2026, 9:15 AM EDT